Order Article Reprints

Zellmer J, Yen H-Y, Kaiser L, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR, et al. Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors. Biomedicines. 2022; 10(12):3102. https://doi.org/10.3390/biomedicines10123102

Zellmer, Johannes, Hsi-Yu Yen, Lena Kaiser, Franz Josef Gildehaus, Guido Böning, Katja Steiger, Marcus Hacker, Peter Bartenstein, Andrei Todica, Alexander R. Haug, and et al. 2022. "Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors" Biomedicines 10, no. 12: 3102. https://doi.org/10.3390/biomedicines10123102

Zellmer, J., Yen, H.-Y., Kaiser, L., Gildehaus, F. J., Böning, G., Steiger, K., Hacker, M., Bartenstein, P., Todica, A., Haug, A. R., & Ilhan, H. (2022). Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors. Biomedicines, 10(12), 3102. https://doi.org/10.3390/biomedicines10123102